Introduction
The larval stage of two cestodes (Echinococcus spp. and Taenia solium) and one trematode (Fasciola spp.) commonly inhabit the human organs and are a frequent cause of human morbidity and mortality. Unlike taeniasis/ cysticercosis and fascioliasis, which are endemic in rural areas in developing countries, hydatid disease is still prevalent in some regions of industrialized countries. New diagnostic technologies, treatment efficacy data from controlled trials, and new control tools including vaccine candidates are now available.
Echinococcosis (E. granulosus/E. multilocularis)
Echinococcosis is still a frequent cause of liver and lung disease in many countries. E. granulosus and E. multilocularis present very different clinical manifestations.
Biology/life cycle
The life cycle of Echinococcus species involve carnivores as final hosts and herbivores as intermediate hosts.
Humans are an incidental intermediate host, since further development of these cestodes depends on ingestion of their larvae by a carnivore [1 ] .
Epidemiology E. granulosus is prevalent in broad regions of Eurasia, in several South American countries and in Africa [2] . In North America most cases are diagnosed in immigrants from endemic countries. Re-emergence seems to have occurred in Bulgaria where the incidence of cystic echinococcosis in children increased from 0.7 to 5.4/100 000 between the 1970s and the mid-1990s, following the collapse of control efforts [2] . In Wales, the prevalence of infected dogs has more than doubled between 1993 (3.4%) and 2002 (8.1%), following policy changes favoring health education over weekly dosing of dogs with praziquantel [2] . E. multilocularis is endemic in the central part of Europe, parts of the near east, Russia, and the central Asian republics, China, northern Japan and Alaska [2] .
Recent findings show major endemic areas for both Echinococcus species in China [3, 4 ] .
Clinical features
In humans, hydatid cysts of E. granulosus are slowly enlarging masses comparable to benign neoplasms; most human infections remain asymptomatic. The clinical manifestations of cystic hydatid disease are variable and are determined by the site, size, and condition of the cysts [1 ] . Hydatid cysts in the liver and the lungs together account for 90% of affected localizations.
In alveolar hydatid disease, the embryo of E. multilocularis seems to localize invariably in the liver of the intermediate host. The hepatic parenchyma is gradually invaded and replaced by fibrous tissue in which great numbers of vesicles, many microscopic, are embedded. Patients eventually succumb to hepatic failure, invasion of contiguous structures, or, less frequently, metastases to the brain [5] .
Diagnosis
Clinical findings such as a space-occupying lesion and residence in an endemic region are suggestive of cystic hydatid disease [4 ] . Abdominal ultrasonography is an important aid to the diagnosis of abdominal cysts. Chest roentgenography permits the detection of echinococcal cysts in the lungs. Computed tomography (CT) scanning is very helpful, especially for diagnosis of nontypical lesions. Portable ultrasonography machines have been applied for field surveys with excellent results [4 ,6] .
Serologic tests are useful to confirm presumptive radiologic diagnoses, although some patients with cystic echinococcosis do not develop a detectable immune response [7, 8] . Hepatic cysts are more likely to elicit an immune response than pulmonary cysts; it appears, however, that, regardless of location, the sensitivity of serologic tests is inversely related to the degree of sequestration of the echinococcal antigens inside cysts.
Alveolar hydatid disease may mimic hepatic carcinoma or cirrhosis in patients of advanced age. Plain roentgenography shows hepatomegaly and characteristic scattered areas of radiolucency outlined by calcified rings 2-4 mm in diameter. The usual CT image of E. multilocularis infection is that of indistinct solid tumors with central necrotic areas and perinecrotic plaque-like calcifications [9 ] . Serologic tests are usually positive at high titers [10] .
Treatment
Surgical removal of hydatid cysts remains the treatment of choice in many countries and it is the preferred treatment when liver cysts are large (>10 cm in diameter), secondarily infected, or located in certain organs (i.e., brain, lung or kidney).
Benzimidazole compounds have been shown to be effective against cystic hydatid disease. Courses of albendazole in a dose of 10-15 mg/kg body weight per day for 28 days are interspersed with drug-free periods of 2 weeks. Approximately a third of patients treated with benzimidazole drugs become cured (e.g. complete and permanent disappearance of cysts) and even higher proportions (30-50%) demonstrate significant regression of cyst size and alleviation of symptoms [11] . Twenty to 40% of cases, however, do not respond favorably. Because of its high scolicidal activity, albendazole is recommended as a prophylactic agent 1-3 months before surgical intervention [12] . The combination of praziquantel and albendazole has been used successfully in the treatment of hydatid disease [12] . Puncture, aspiration, injection and re-aspiration (PAIR) consists of percutaneous puncture using sonographic guidance, aspiration of substantial amounts of the cyst fluid, and injection of a protoscolicidal agent, usually hypertonic saline for at least 15 min, followed by reaspiration of cyst contents [13] . A metaanalysis comparing the use of PAIR and surgical treatment for liver hydatid cysts found fewer complications and a shorter hospital stay in the PAIR-treated group [14] .
Alveolar hydatid disease has a high mortality rate with or without surgery. With metastases to the brain, death occurs within a few months after onset of neurologic disorders. Long-term treatment with mebendazole (50 mg/kg per day) or albendazole (10-15 mg/kg) inhibits growth of larval E. multilocularis, reduces metastasis, and enhances both the quality and length of survival; prolonged therapy may eventually be larvicidal in some patients [15] . Liver transplantation has been employed successfully on otherwise terminal cases [16] . Preliminary in-vitro studies suggest nitazoxanide and albendazole may be parasitocidal against E. multilocularis larvae [17] but further efficacy trials in humans are warranted to assess efficacy.
Prevention and control
Large-scale programs of control of cystic hydatid disease have had noteworthy success only in Iceland, New Zealand, Australia, Tasmania, and Cyprus, where hydatid disease has been eliminated [18 ] . In these countries, the programs have been based on public education combined with strict regulations directed particularly toward control of dogs. Continental programs, such as those of Argentina, Chile and Uruguay, have not experienced this level of success [19 ] . Promising advances include the development of a recombinant vaccine (EG95) against ovine echinococcosis [20] and a vaccine against the dog tapeworm stage [21 ] . Control of E. multilocularis presents a difficult problem of potentially increasing importance.
Taeniasis/cysticercosis (Taenia solium)
Taenia solium cysticercosis is the most important cause of acquired epilepsy in developing countries and probably in the world.
Biology/life cycle
Humans are the only definitive host of Taenia solium and acquire the intestinal tapeworm by ingestion of contaminated pork containing larval cysts (cysticerci). The tapeworm, and thus the tapeworm carrier, are the only source of cysticercosis infection for pigs or for other humans. Pigs (the usual intermediate host) acquire cysticercosis by eating stools contaminated with tapeworm proglottids or infective eggs in places where deficient sanitation exists. Humans get infected by fecal-oral contamination from a tapeworm carrier, commonly in the household or other close environment [22] .
In highly endemic areas, the prevalence of human taeniasis usually ranges between 1 and 2%, while most of the pigs will show serological evidence of exposure to Taenia solium, and over 20% of them may harbor cysts in their flesh. Infected pigs cluster around tapeworm carriers, with clustering extending somewhat beyond the household limits [23 ] . Alternative dispersion mechanisms, including the role of pigs as mechanical vectors, insects, or other vectors contributing to this widespread range, have been suggested [23 ] .
Diagnosis
Diagnosis of human tapeworm carriers, extremely important for control purposes, has benefited from the availability (albeit somewhat limited) of coproantigen detection tests [24] . Stage-specific serological assays for tapeworm detection have been developed and should be of use. Their main drawback is the lack of information on antibody longevity, which should affect the predictive value of such assays.
Diagnosis of neurocysticercosis is mainly made by neuroimaging. MRI is the most sensitive technique for most types of neurocysticercosis, although it may be of poor use for detection of calcified lesions. CT, more available in endemic regions and less expensive, is a useful alternative, particularly if new generation scanners can be used. Serological assays confirm the diagnosis. The assay of choice is an immunoblot using seven purified glycoprotein antigens. This test has 98% sensitivity and 100% specificity in patients with more than one lesion. Sensitivity in single-lesion cases may drop to 70%. Synthetic or recombinant versions of these antigens should facilitate the development of new versions of the assay, less dependent on biological material [25] .
Antigen-detection assays could demonstrate the presence of live parasites. The sensitivity of these assays seems to be low in cases of intraparenchymal neurocysticercosis. They may, however, become an important monitoring tool for patients with extraparenchymal neurocysticercosis [26, 27 ] .
Clinical manifestations and treatment
Controlled field studies have consistently demonstrated the association between neurocysticercosis and epilepsy [28 ,29-32] . In clinical settings, there is now a consensus that antiparasitic therapy is of benefit in most forms of active neurocysticercosis [33 ,34] . Some groups have proposed the use of increased doses of albendazole (30 mg/kg/day instead of the current 15 mg/kg/day dose) but more controlled evidence on its safety and efficacy are still awaited. Steroids are key in modulating the inflammation resulting from the death of the cysts following antiparasitic treatment, and apparently have an individual, specific beneficial effect in the management of single intraparenchymal brain enhancing lesions (solitary cysticercal granuloma) [35 ] . Long-term, high-dose steroid therapy may be required in cases of extraparenchymal neurocysticercosis, with potentially serious side effects. Methotrexate has been introduced as a steroidsparing agent in this type of patient [36 ] . A subset of patients still requires surgery, mainly to place cerebrospinal fluid shunt mechanisms or to extirpate intraventricular or giant cysts. Neuroendoscopical removal of cysts or fenestration of the third ventricle appear to be promising, less invasive techniques [37 ,38 ] .
Prevention and control
Taeniasis/cysticercosis is considered an eradicable disease. Control efforts are centered on the definition of a sustainable, economic, and efficient strategy to interrupt transmission. Several vaccine candidates are now described, with an Australian vaccine demonstrating almost complete protection [39 ,40,41,42 ,43 ] . A wide scale elimination program sponsored by The Bill and Melinda Gates Foundation is ongoing in northern Peru, aiming to eliminate transmission in an area of 100 000 inhabitants.
Fascioliasis (Fasciola hepatica/F. gigantica)
Infections with F. hepatica and F. gigantica are a frequent cause of liver disease in endemic areas.
Biology/life cycle
Fascioliasis, infection with the liver flukes, Fasciola hepatica and F. gigantica, results from ingestion of immature stages (metacercariae) on uncooked aquatic vegetation or free swimming in water worldwide, especially in sheep and cattle-raising areas [44] . When swallowed by susceptible mammals, the infective metacercariae excyst, and the larvae penetrate the intestinal wall into the peritoneum and pass through the liver capsule and tissues to the biliary tract [45 ] . The hermaphroditic adult flukes live in the mammalian hosts' common and hepatic bile ducts. Operculate ova are evacuated in the feces. Free swimming larvae (miracidia) emerge from the eggs in fresh water habitats and penetrate or are ingested by lymnaeid snails in which they multiply and are released as free-swimming cercariae which attach and encyst as metacercariae on watercress and other aquatic plants. Adult flukes can live as long as 10 years.
Epidemiology
F. hepatica infections in livestock have been reported from all continents except Antarctica, with highest rates of infection in temperate zones of Bolivia, Peru, Egypt, Iran, Portugal, and France. F. gigantica has a more restricted geographic distribution limited to tropical environments in parts of Africa, the Middle East and south and eastern Asia [44] . Sporadic cases of infection in humans, usually imported, have been diagnosed in the United States [46] . Most patients report having ingested uncooked aquatic vegetation or pond water.
Diagnosis
The diagnosis should be considered in the patient who lives or has traveled to endemic areas with a history of ingesting fresh water plants or drinking untreated water and having fever, right-upper quadrant pain or intrahepatic cystic lesions together with absolute peripheral blood eosinophilia [46] . Characteristic lesions on hepatic imaging include hypodense tortuous and branching linear tracks under the capsule corresponding to necrosis, and eosinophilic inflammatory infiltrates along the path of larval migration [47] . Endoscopic retrograde cholangiopancreatography (ERCP) is useful to confirm the location of the trematode in the extrahepatic biliary tract [48 ,49 ].
Definitive diagnosis is made by demonstrating eggs in samples of stool, bile or duodenal aspirates, specific antibodies in serum or by recovering worms at surgery. Quantitation of eggs per gram of feces may underestimate the fluke burden because of the 'crowding effect' whereby higher worm burdens may result in decreased egg production [50 ] . Stool examinations and serologic tests are less useful during acute infection, however, because symptoms develop 1-2 months before eggs or antibodies are detectable in stool or serum, respectively [50 ,51 ] .
Clinical manifestations and treatment
Infection with F. hepatica has two distinct clinical phases corresponding to the migratory stages of its life cycle (acute) and to the presence of the worms in their final habitat in the bile ducts (chronic). Many cases are asymptomatic, but mechanical liver damage results from the migrations of juvenile flukes and possibly chemical factors released by the fluke and may compromise liver function, which is reflected in changes of plasma protein concentration (albumin, globulin) and increased levels of hepatic enzymes in blood [45 ,50 ] ; severity of liver damage is related to fluke burden which may not be reflected in the fecal egg concentration because of the crowding effect [50 ] . Marked eosinophilia is seen in most infected persons, and abdominal pain, intermittent fever, weight loss and urticaria are common. Aberrant migration may produce migratory nodules in the skin, painful inflammation of the intestinal wall, and lesions in the lung, brain, genitourinary tract or elsewhere.
Within several weeks to months, the symptoms and signs of the acute phase subside as the worms enter the bile ducts. Chronic fascioliasis is usually subclinical, but some persons have symptoms due to inflammation and intermittent obstruction of bile ducts that resemble biliary colic and cholecystitis, and occasionally there is an ascending cholangitis [49 ,50 ] .
Unlike infections with other flukes, fascioliasis responds poorly to praziquantel. First line treatment is a single oral dose of triclabendazole (10 mg/kg), a well tolerated benzimidazole derivative used in veterinary practice that is highly effective against mature and immature flukes [52, 53 ] . (Triclabendazole has not been approved for use in humans in the USA. Upon obtaining permission from the FDA, the drug is available from International Apotheke in Zurich, Switzerland, Tel: +41 44 211 24 32. Further information can be obtained from the CDC Parasitic Diseases Drug Service, Tel: +1 404 639 3670.) Resistance to triclabendazole is now reportedly common in Ireland, the United Kingdom and Australia [53 ] , however, and prompts research for understanding mechanisms of resistance and a search for new fasciolicide compounds [54 -56 ] . Treatment with bithionol requires 10-15 doses and causes frequent side effects. (Bithionol is available under an investigational new drug protocol from the CDC Drug Service, Centers For Disease Control and Prevention, Atlanta, GA 30333, USA; Tel: +1 404 639 3670; evenings, weekends, or holidays: þ1 404 639 2888.) Nitazoxanide, a broad spectrum antiparasitic drug given orally to adult patients as one 500 mg tablet every 12 h for 6-7 consecutive days, produced rapid clinical improvement and clearance of infection as determined by hepatic imaging findings and negative stool examination [57] . Clinical trials involving more than 300 patients demonstrated cure rates of 49-87% with few and minor side effects (vomiting and abdominal pain) [57, 58] .
Prevention and control
Avoidance of potentially contaminated aquatic vegetation is the most reliable method of prevention. Metacercariae attached to vegetation retain their viability and infectivity for 2-4 weeks despite dipping in potassium permanganate as a preventive [59 ] . Recent progress has been reported in development of a vaccine for use in sheep [60 ] .
Conclusion
While there have been significant improvements in most areas of knowledge in these three larval helminth infections, they continue to be a significant cause of human disease in many regions of the world. Improved control interventions are still required.
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